A Better Newspaper

If Washington Takes Equity in AI Firms, the Copyright Wars Get Rewritten

The piece examines how proposals floated under Sen. Sanders' and President Trump's plans for the US government to take equity stakes in American AI companies could affect the 100-plus copyright lawsuits currently pending against those companies. The author frames government ownership as a 'wildcard' that could materially alter the trajectory of that litigation.

Context: For a litigator-entrepreneur this is the sleeper issue: sovereign-immunity doctrines, settlement incentives, and standing all shift the moment the United States becomes a part-owner of a defendant. If the government has skin in the game, expect pressure toward licensing frameworks and away from rulings that would gut model training — a potential moat for incumbents and a new fee market for IP counsel structuring those licenses.

Galloway: The Real Brake on US AI Isn't Chips — It's the Data Center Permitting Fight

Galloway argues the biggest obstacle to AI in America is neither supply chains nor chips, but the domestic resistance to building AI data centers. He contrasts US cultural and policy friction with China's broad public enthusiasm for adopting new technologies, suggesting that openness ultimately advantages China in the AI race.

Context: This sharpens the 'compute scarcity' thesis: if the binding constraint is land, power, and local politics rather than GPUs, the money flows to whoever can site, power, and permit capacity — utilities, grid interconnect, behind-the-meter generation, and the developers who solve NIMBY. That's where underbuilt opportunity sits, and where regulatory expertise becomes a billable edge.

A New Drug Target for Alzheimer's and Parkinson's: Redirect, Don't Block

Researchers at Baylor College of Medicine report that tubulin — the protein that builds the cell's internal transport scaffolding — can redirect the Tau and alpha-synuclein proteins implicated in Alzheimer's and Parkinson's away from forming toxic clumps and toward productive cellular work. The approach differs from conventional strategies that try to stop these proteins from aggregating in the first place.

Context: Decades of Alzheimer's drug development have focused on clearing or preventing protein aggregates, with a long trail of clinical failures. A mechanism that channels misfolding-prone proteins back into normal function — rather than fighting aggregation head-on — is a genuinely different therapeutic angle, and one worth watching for biotech licensing activity if it holds up beyond cell models.

The Brain Builds Itself by Breaking Its Own DNA

Researchers found that as newborn neurons squeeze through tight spaces to reach their destinations in the developing brain, the physical journey routinely causes double-strand breaks — among the most severe forms of DNA damage. The young brain has evolved the ability to repair this damage almost immediately.

Context: Beyond the basic-science elegance, this reframes how we think about neurodevelopmental disorders and possibly age-related decline: if neuron migration depends on a damage-and-repair cycle, defects in that repair machinery become a plausible disease mechanism — and a target for diagnostics or intervention.

Long-Lived Families Point to an Inflammation-Taming Gene

A study of long-lived families identified rare genetic variants that may help people stay healthier longer as they age. One standout mutation appears to temper inflammation, potentially delaying disease and extending years of healthy living.

Context: The longevity field has shifted from chasing lifespan to 'healthspan,' and inflammation ('inflammaging') is its central target. Rare protective variants in unusually healthy families are exactly how validated drug targets get discovered — the PCSK9 cholesterol drugs followed this same playbook. Worth tracking which target this maps onto.

Chinese Sodium Battery Matches Tesla — and the Lithium Trade Should Be Nervous

Researchers found a Chinese sodium-ion battery performing far better than expected, with production quality and design features comparable to Tesla's batteries. The report notes that if engineers can solve cold-weather charging and energy density, sodium could become a cheaper and more abundant alternative to lithium for EVs and grid-scale storage.

Context: The opportunity isn't the battery — it's the supply chain dislocation. Sodium is orders of magnitude more abundant than lithium and free of the cobalt/nickel chokepoints that gate Western EV economics. If sodium becomes 'good enough' for stationary storage first (where energy density matters less and cold-weather charging is irrelevant), the addressable market is grid arbitrage and data-center backup — exactly where capital is flooding. Watch for distress in marginal lithium miners and a re-rate of anyone holding sodium IP or domestic cathode capacity outside China.

O'Leary's €150mn Ryanair Bet: A Master Class in Aligning Pay to Operational Outperformance

Michael O'Leary, longtime boss of Europe's biggest airline, has signed a new contract that includes a bumper share award contingent on hitting ambitious targets, putting him in line for a payout of up to €150mn.

Context: The strategic read isn't the number, it's the structure: a deeply contingent, target-gated equity grant in a low-margin commodity industry where most peers are chronically underwater. O'Leary built the only consistently profitable ultra-low-cost airline in Europe by treating cost discipline as a religion. The replicable lesson for operators and funders: in sectors written off as un-investable, the alpha is operational, not cyclical — and pay packages that pay only on outperformance are a tell that the board genuinely believes there's room to run.

Major Review Concludes Vaping Likely Causes Lung and Oral Cancer — Earliest Hard Causation Signal for Next-Gen E-Cigarette Tort

Researchers have concluded that nicotine vapes are likely to cause lung and oral cancers, drawing on evidence spanning human biomarkers, animal models, and laboratory studies. The findings challenge the framing of vaping as a harmless alternative to smoking and suggest health risks may emerge sooner than many expected. The review is a synthesis of existing evidence rather than a single new clinical trial.

Context: Existing JUUL/e-cigarette litigation (the JLI MDL and the consolidated California proceedings) has centered overwhelmingly on youth nicotine addiction and marketing — NOT on cancer endpoints, which were considered too long-latency to litigate. A credible causation review tying vaping to specific cancers is the kind of biomarker-plus-mechanism foundation that converts an addiction docket into a personal-injury/wrongful-death docket with far higher per-plaintiff value. Signal Strength: 6/10 — high long-term ceiling, but latency and the 'likely' hedge mean specific-causation Daubert battles are years away. Plaintiff Profile: long-term vape users (including former JUUL-era adolescents now reaching their late 20s–30s) presenting with lung or oral malignancies. Next Step: pull and read the underlying review in full to confirm journal, methodology, and whether it identifies specific products or constituents (e.g., carbonyls, flavorants); begin preserving the early-adopter user cohort and tracking FAERS/MAUDE-adjacent adverse reporting for cancer signals.

US and Iran Head to Switzerland as Tehran Claims Hormuz Closure

Iran says it has closed the Strait of Hormuz in response to Israeli attacks in Lebanon, a claim the US disputes. US-Iran talks are set to begin Sunday in Switzerland, according to Pakistan, amid the escalating tensions. The US has contested Tehran's assertion that the waterway is shut.

Context: Roughly a fifth of global oil and a large share of LNG transits Hormuz; any genuine or sustained disruption would spike crude and tanker rates immediately. The juxtaposition of a chokepoint threat with imminent negotiations suggests Tehran is using the strait as leverage at the table rather than seeking a prolonged closure.

Polymarket: US invades Iran before 2027 14% · Iranian regime falls by June 30 0%

Reported US-Iran MOU Leaves Israel on the Sidelines

Bloomberg reports the US and Iran have a new Memorandum of Understanding, with Israel excluded from the talks. Jerusalem reporter Dan Williams describes the situation as an embarrassment for Prime Minister Netanyahu, who has been sidelined as Washington negotiates directly with Tehran.

Context: A US-Iran détente that bypasses Israel marks a notable shift in the regional alignment Washington has maintained for years. For markets, a credible diplomatic track would cap the geopolitical risk premium on oil; for Netanyahu, it narrows his room to escalate unilaterally.

Fed's Preferred Inflation Gauge Seen Reinforcing the Case for Hikes

Bloomberg reports the latest update to the Federal Reserve's favorite inflation gauge is unlikely to challenge a growing consensus at the central bank around the need for interest-rate hikes this year.

Context: A Fed leaning toward hikes — rather than the cuts markets spent much of last year pricing — reprices the entire risk curve: higher discount rates pressure equity multiples and rate-sensitive assets, and reflect inflation proving stickier than the soft-landing narrative assumed.

Colombia's Worsening Internal Conflict Frames Presidential Race

BBC reports that Colombia's escalating and brutal internal conflict is shaping its presidential election, pitting a left-wing senator who backs negotiations with armed gangs against an outsider endorsed by Trump.

Context: Colombia is a key US trade and security partner in Latin America and a major supplier of coffee, oil, and coal; a destabilized political transition affects regional migration flows and US counternarcotics posture.

ICON BR #97 Bronco — Six-Figure Build, Likely Five-Figure Discount

This 1971 Ford Bronco roadster is #97 in ICON 4x4's BR series, completed in 2022 and delivered to the current owner. It rides on an Art Morrison chassis with Currie axles, air lockers, Fox remote-reservoir coilovers, and Brembo calipers, powered by a 5.0-liter Coyote V8 backed by a five-speed manual and an Atlas twin-stick transfer case. Finished in Grabber Orange with heated bucket seats, onboard air, and power-retractable side steps.

Context: ICON's new BR Broncos run roughly $250k–$300k to build with a long wait list. A clean, low-use 2022 example on the secondary market typically trades below cost — the rare case where the depreciation hit on a hand-built rig works in the buyer's favor. This is the best object in today's batch for a man who wants a do-anything overlander that's also an appreciating piece.

14k-Mile, One-Owner TJ Rubicon 4.0 Manual — A Stored Time Capsule

This 2003 Jeep Wrangler Rubicon was bought new by the seller and shows just 14k miles. It pairs the bulletproof 4.0-liter inline-six with a five-speed manual and Rock-Trac transfer case, plus front and rear Dana 44 axles with factory Tru-Lok lockers. Sold with window sticker, owner's manual, service records, and a clean Colorado title.

Context: The 4.0/manual/factory-locker TJ Rubicon is the configuration the off-road community has decided is the high-water mark for the model, and clean low-mileage examples have been climbing steadily. At 14k original miles this is essentially a new one — closer to a collectible than a daily driver, and almost impossible to replicate.

Jensen Interceptor Mk III at No Reserve — Grand Touring on the Cheap

This 1974 Jensen Interceptor Mk III is finished in white over red leather and powered by a Chrysler 440ci V8 with a three-speed automatic and limited-slip diff, now running an Edelbrock intake, Holley four-barrel, roller lifters, and an aluminum radiator with dual fans. Suspension, steering, brakes, wiring harness, and seat cushions have been overhauled or replaced since 2017, with a stainless exhaust added. Offered with no reserve.

Context: The Interceptor is Italian-bodied (Vignale), American-powered British exotica that has long traded for a fraction of contemporaries with similar presence. The no-reserve format plus the worst-of-it mechanical work already done — and Mopar big-block parts availability — makes this the rare classic where buy-in and running costs both stay sane. Buy on the dip.

34k-Mile C6 Corvette 3LT — The Last Cheap LS2 Window Is Closing

This 2006 Corvette coupe was bought by the seller in 2012 and has covered 34k miles, optioned in Machine Silver over Ebony with the loaded 3LT package adding heated power seats, head-up display, and power steering column. Power comes from the 6.0-liter LS2 V8, here paired with a six-speed automatic and limited-slip diff. Sold with owner's manual and a clean title.

Context: Early C6s remain one of the best performance-per-dollar plays in the market, but clean low-mileage cars are getting harder to find as the cheap ones get modified or thrashed. The automatic dampens collector upside, so this is a buy-and-enjoy proposition rather than an appreciation play — worth it only if it sells right.